Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 3, 2002, Pages 315-317

  Torti, Carlo ^a   Patroni, Andrea ^a   Tinelli, Carmine ^a   Sleiman, Intissar ^a   Quiros Roldan, Eugenia ^a   Puoti, Massimo ^a   Castelli, Francesco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HEPATITIS C VIRUS; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SUPERINFECTION;

EID: 0036500404     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200203010-00015     Document Type: Letter

References (7)

1. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy
2. Does antiretroviral-induced hyperlipidemia constitute a cardiovascular risk?
3. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, aquitane cohort, France, 1996 to 1998
4. Interactions between metabolic disorders (diabetes, gallstones, and dyslipidaemia) and the progression of chronic hepatitis C virus infection to cirrhosis and hepatocellular carcinoma: A cross-sectional multicentre survey
5. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy
6. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy
7. Resting energy expenditure in chronic hepatitis C